Frankfurt - Delayed Quote EUR
Rocket Pharmaceuticals, Inc. (9IP1.F)
2.4930
+0.0360
+(1.47%)
At close: June 13 at 9:15:05 AM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 14 | 15 |
| Avg. Estimate | 4.36M | 326.78k | 10.73M | 90.4M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 48M | 2.5M | 143M | 305.95M |
| Year Ago Sales | -- | -- | -- | 10.73M |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 742.69% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 9IP1.F | -- | -- | -- | -- |
| S&P 500 | 13.13% | 2.41% | 7.55% | 14.06% |
Upgrades & Downgrades
| Maintains | Canaccord Genuity: Buy to Buy | 6/3/2025 |
| Maintains | B of A Securities: Buy to Buy | 5/28/2025 |
| Maintains | BMO Capital: Outperform to Outperform | 5/28/2025 |
| Maintains | Scotiabank: Sector Outperform to Sector Outperform | 5/28/2025 |
| Downgrade | Leerink Partners: Outperform to Market Perform | 5/28/2025 |
| Maintains | Chardan Capital: Buy to Buy | 5/28/2025 |
Related Tickers
38I.SG Intellia Therapeutics Inc
7.15
-0.56%
5CV.MU CureVac NV
4.7540
+0.72%
DRMA Dermata Therapeutics, Inc.
0.7123
-2.96%
TERN Terns Pharmaceuticals, Inc.
3.8800
-1.27%
ELEV Elevation Oncology, Inc.
0.3817
+0.39%
SPRY ARS Pharmaceuticals, Inc.
15.39
+6.88%
INAB IN8bio, Inc.
2.2600
-5.04%
HOTH Hoth Therapeutics, Inc.
1.3000
-8.45%
CTXR Citius Pharmaceuticals, Inc.
0.8746
-4.93%
IBRX ImmunityBio, Inc.
3.0700
-3.76%